2022 World Conference on Lung Cancer (ePosters)-EP08.02-010. Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China

EP08.02-010. Low-Dose Dacomitinib as First-Line Therapy for Driver-Positive Advanced Non-small Cell Lung Cancer: A Multicenter Real-World Study in China

Back to course

Pdf Summary

A Chinese multicenter real-world study evaluated the efficacy and safety of using a lower dose of dacomitinib (30 mg/day) as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR driver gene expression. The study included NSCLC patients from several hospitals in China who were diagnosed between January 2019 and June 2021. The inclusion criteria for the study were age 18 years or above, clear diagnosis of NSCLC based on pathological results, EGFR mutation detected in lung tissue, peripheral blood, or pleural effusion, and at least one measurable lesion in the lung. The exclusion criteria included incomplete clinical case data, wild-type EGFR or other gene mutations, combination chemotherapy, radiation therapy, or immunotherapy during treatment, no traceable imaging data, and symptomatic brain metastases.<br /><br />The results of the study showed that low-dose dacomitinib treatment had good efficacy in patients with EGFR classic mutation. Out of the 30 enrolled patients, 19 achieved a partial response (PR) and 11 had stable disease (SD). The overall response rate (ORR) was 63.3%, and the disease control rate (DCR) was 100%. The study also found that the adverse reactions of grade 3 and above were minimal. Among the patients with brain metastases, one achieved PR of the intracranial lesions, and one had SD.<br /><br />The study suggests that a lower dose of dacomitinib (30 mg/day) as first-line therapy can be effective and well-tolerated in NSCLC patients with EGFR classic mutation. This could provide an alternative treatment option for patients who may not tolerate the higher dose of dacomitinib (45 mg/day) used in previous clinical trials. Further studies are needed to validate these findings and explore the long-term outcomes of low-dose dacomitinib treatment in this patient population.

Asset Subtitle

Liang Gong

Meta Tag

Speaker Liang Gong

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Chinese multicenter study

lower dose dacomitinib

first-line treatment

advanced non-small cell lung cancer

NSCLC patients

EGFR driver gene expression

efficacy

safety

EGFR classic mutation

alternative treatment option